Drug Insights

Unlock the Power of Synapse: A Guide to Searching Epinephrine

22 March 2024
2 min read

Epinephrine, a minute molecule drug, exerts its action as an adrenergic receptor agonist by targeting the adrenergic receptor, exhibiting an extensive list of active indications. These encompass intermittent asthma, mydriasis, hypersensitivity, anesthesia, bronchial spasm, hemorrhage, hypotension, shock, anaphylaxis, and heart arrest. Interestingly, the medication was initially approved by Medeca Pharma in November 1967. By stimulating the sympathetic nervous system, epinephrine heightens heart rate and blood pressure while also dilating the airways. The route of administration, whether through injection, inhalation, or topical application, is contingent on the specific indication being treated. In summary, epinephrine is a versatile medication that plays a vital role in emergency settings, treating a broad spectrum of medical conditions, including anaphylaxis, shock, and heart arrest. Click on the image below to begin the exploration journey of Epinephrine through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Orchard Therapeutics Gains FDA Approval for Lenmeldy™ (atidarsagene autotemcel) for Early-Stage Metachromatic Leukodystrophy in Children
Latest Hotspot
3 min read
Orchard Therapeutics Gains FDA Approval for Lenmeldy™ (atidarsagene autotemcel) for Early-Stage Metachromatic Leukodystrophy in Children
22 March 2024
Orchard Therapeutics has obtained U.S. FDA endorsement for Lenmeldy™, a proprietary treatment branded as atidarsagene autotemcel, designed exclusively for young patients diagnosed with early-stage Metachromatic Leukodystrophy.
Read →
What is the meaning of off-label use?
"What" Series
2 min read
What is the meaning of off-label use?
22 March 2024
Off-label use is prescribing or administering a drug in a way not formally sanctioned by regulatory bodies like the FDA or EMA, such as for unapproved conditions, age groups, or dosages.
Read →
Actinium-Based PSMA Radioconjugate Deal Targets Prostate Cancer Treatment and Development
Latest Hotspot
3 min read
Actinium-Based PSMA Radioconjugate Deal Targets Prostate Cancer Treatment and Development
22 March 2024
The deal encompasses a clinical-phase actinium radioconjugate aimed at PSMA to combat prostate cancer, a collection of radioconjugate products in development, and cutting-edge research, development, and production infrastructure.
Read →
How to Effectively Search for Progesterone on Synapse
Drug Insights
2 min read
How to Effectively Search for Progesterone on Synapse
22 March 2024
Progesterone, a diminutive molecule drug, acts as a modulator of the progesterone receptor (PR), exhibiting a broad spectrum of active indications.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.